Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis

BACKGROUND: The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC. METHODS: We conducted a t...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Moritz, Posch, Florian, Kiem, Dominik, Barth, Dominik, Horvath, Lena, Stotz, Michael, Schaberl-Moser, Renate, Pichler, Martin, Greil, Richard, Jost, Philipp J., Seeber, Andreas, Amann, Arno, Schlick, Konstantin, Gerger, Armin, Riedl, Jakob M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488508/
https://www.ncbi.nlm.nih.gov/pubmed/34616490
http://dx.doi.org/10.1177/17588359211039930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488508/
https://www.ncbi.nlm.nih.gov/pubmed/34616490
http://dx.doi.org/10.1177/17588359211039930

Ejemplares similares